Wedding Season Demand for Weight-Loss Drugs
The drive for a transformed look for wedding ceremonies is reshaping India's weight-loss drug market. Clinics are marketing GLP-1 drugs, like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy, in "pre-wedding" packages. This demand, fueled by societal expectations and a desire for quick results, is causing a surge in inquiries for these prescription drugs. Over 20% of recent queries for obesity injections have come from soon-to-be brides, according to doctors who report frequent requests timed with wedding dates. Eli Lilly states Mounjaro is for approved medical uses under supervision, and Novo Nordisk similarly cautions against off-label use. While approved for diabetes and obesity, the push for aesthetic improvement is creating a market segment beyond standard medical guidelines.
Mounjaro Dominates India Market Over Wegovy
Eli Lilly's Mounjaro quickly became India's top-selling drug by value, earning significant revenue soon after its launch. By October 2025, Mounjaro sales reached ₹100 crore ($11.38 million), outperforming established drugs. Reports suggest its volume consumption is ten times that of Novo Nordisk's Wegovy. Wegovy, meanwhile, has seen weak sales in India despite significant price cuts. By January 2026, Mounjaro's annual sales reached ₹746 crore, far ahead of Wegovy's ₹72 crore. Mounjaro's stronger market position is likely due to its combination mechanism, which offers potentially greater effectiveness. Novo Nordisk has responded with substantial price reductions on Wegovy to improve its market access and competitiveness.
Generics Flood Market, Regulators Tighten Grip
The semaglutide patent's expiry in March 2026 allows Indian drugmakers to launch cheaper generic versions of Ozempic and Wegovy. Many companies are expected to release new brands, with some generics priced as low as Rs325 per week. This wave of affordable options will likely broaden market access but also heightens worries about misuse and illegal sales. India's drug regulator is increasing inspections of pharmacies, clinics, and wholesalers to stop improper practices and false advertising. Official warnings emphasize that these GLP-1 drugs require a prescription and must be used only under a doctor's care, not for cosmetic purposes.
Company Valuations and Growth Prospects
Eli Lilly and Novo Nordisk show different financial pictures and investor views. Eli Lilly has a large market value, near $900 billion, with a price-to-earnings (P/E) ratio around 40-43, indicating strong investor confidence. Its growth is supported by a strong pipeline of obesity and diabetes drugs, including the new oral medication Foundayo. Novo Nordisk has a market value of about $164 billion and a lower P/E ratio of roughly 10-11, suggesting more investor caution. Investor sentiment for Novo Nordisk is mixed, with price targets showing limited potential gains. However, recent setbacks in trials and tough competition have cooled expectations for Novo Nordisk, leading some observers to view its stock less favorably.
Key Risks and Challenges Ahead
The rising demand for GLP-1 drugs in India, especially for non-medical uses, carries significant risks. Regulators are working to stop misuse, warning of serious health problems from unsupervised use. While cheaper generic drugs will improve access, they also increase price competition and raise quality concerns. Novo Nordisk faces threats to its pricing and revenue from Mounjaro's market gains and the coming wave of generics. Eli Lilly, despite its strong position, also faces competition and potential regulatory attention as the market develops. If GLP-1 treatments become widely available at lower prices and focus heavily on cosmetic use, their long-term value could be reduced unless they are strictly managed within medical and ethical limits. How companies manage market entry and competition will be key to their success.